Rivamer Tablet
Rivastigmine
1.5mg
Sun Pharmaceutical Industries Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 16.80 NPR |
Indications
Rivamer Tablet is used for:
Severe dementia in Alzheimer's disease, Parkinson Dementia
Adult Dose
Alzheimer Dementia
Oral
Indicated for mild-to-moderate dementia of the Alzheimer's type
Initial: 1.5 mg PO q12hr
Increase by 1.5 mg/dose q2Weeks; not to exceed 6 mg PO q12hr
Maintenance: 3-6 mg PO q12hr (higher end may be more beneficial)
Transdermal
Indicated for mild, moderate, and severe dementia of the Alzheimer's type
Initial: Apply 4.6 mg q24hr
Dose titration: May increase dose to 9.5 mg q24hr after a minimum 4 weeks if well tolerated; after an additional 4 weeks, may further increase to 13.3 mg patch if needed
Mild-to-moderate Alzheimer disease: Effective dosage range is 9.5-13.3 mg/24 hr
Moderate-to-severe Alzheimer disease: Effective dose is 13.3 mg/24 hr
Replace with new patch q24hr
Parkinson Dementia
Oral
Initial: 1.5 mg PO q12hr
Increase by 1.5 mg/dose q4Weeks; not to exceed 6 mg PO q12hr
Maintenance: 1.5-6 mg PO q12hr
Transdermal
Initial: Apply 4.6 mg q24hr
May increase dose to 9.5 mg q24hr after a minimum 4 weeks if well tolerated; after an additional 4 weeks, may further increase to 13.3 mg patch if needed
Transdermal
Mild-to-moderate hepatic impairment: Not to exceed 4.6 mg q24hr
Child Dose
Renal Dose
Transdermal
Renal impairment: No dosage adjustment required
Administration
Should be taken with food.
Contra Indications
Hypersensitivity to other carbamate derivatives. Severe hepatic impairment.
Precautions
Patients with sick sinus syndrome or conduction defects, resp diseases. Cholinergic stimulation may increase gastric acid secretion. May exacerbate urinary obstruction and seizures. Pregnancy. Renal impairment, mild to moderate hepatic impairment. Monitor body wt. Asthma or obstructive pulmonary disease. May worsen extrapyramidal symptoms. Lactation.
Lactation: Unknown if excreted in milk; not recommended
Pregnancy-Lactation
Interactions
Not to be used with other cholinomimetic drugs that might interfere with the activity of anticholinergic medications. May exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Tobacco smoking may increase its clearance.
Adverse Effects
Side effects of Rivastigmine :
>10%
Nausea (PO 47%; patch 21%),Vomiting (PO 31%; patch 6-19%),Dizziness (PO 21%; patch 2-7%),Diarrhea (PO 19%; patch 6-10%),Headache (PO 17%; patch 3-4%),Anorexia (PO 17%; patch 3-9%),Abdominal pain (PO 13%; patch 2-4%)
1-10%
Decreased weight (3-8%),Insomnia (PO 9%; patch 1-4%),Anxiety (PO 5%; patch 3%),Asthenia (PO 6%; patch 2-3%),Vertigo (2%),Fatigue (2%)
Potentially Fatal: Serious GI reactions such as anorexia, vomiting and weight loss.
Mechanism of Action
Rivastigmine reversibly inhibits hydrolysis of acetylcholine by cholinesterases thus increasing acetylcholine present in the CNS. It is selective for the CNS and is used for the symptomatic treatment of dementia in Alzheimer's disease and idiopathic Parkinson's disease.
Note
Rivamer 1.5mg Tablet manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Rivastigmine. Rivamer is availble in Nepal.
Farmaco Nepal drug index information on Rivamer Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.